Overslaan en naar de inhoud gaan

 Wetenschapelijke artikelen

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.

Auteurs : Bachy E, Houot R, Feugier P, Bouabdallah K, Bouabdallah R, Virelizier EN, Maerevoet M, Fruchart C, Snauwaert S, Le Gouill S, Marolleau JP, Molina L, Moluçon-Chabrot C, Thieblemont C, Tilly H, Bijou F, Haioun C, Van Den Neste E, Fabiani B, Meignan M, Cartron G, Salles G, Casasnovas O, Morschhauser F
Jaar : 2022
Journal : Blood
Volume : 139
Pagina's : 2338-2346

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.

Auteurs : Leupin N, Zinzani PL, Morschhauser F, Dalle S, Maerevoet M, Michot JM, Ribrag V, Offner F, Beylot-Barry M, Moins-Teisserenc H, Zwaenepoel K, de Winne K, Battistella M, Hultberg A, Gandini D, Moshir M, Jacobs J, Delahaye T, Khan A, Zabrocki P, Silence K, Van Rompaey L, Borg C, Motta G, Melle F, Calleri A, Pauwels P, de Haard H, Pileri S, Bagot M
Jaar : 2022
Journal : Cancer
Volume : 128
Pagina's : 1004-1014

Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.

Auteurs : Schuster M, Zijlstra J, Casasnovas RO, Vermaat JSP, Kalakonda N, Goy A, Choquet S, Neste EVD, Hill B, Thieblemont C, Cavallo F, De la Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Follows G, Egyed M, Offner F, Vassilakopoulos T, Samal P, Ku M, Ma X, Corona K, Chamoun K, Shah J, Shacham S, Kauffman MG, Canales M, Maerevoet M
Jaar : 2022
Journal : Clin Lymphoma Myeloma Leuk
Volume : 22
Pagina's : 483-494

Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.

Auteurs : Casasnovas RO, Follows G, Zijlstra JM, Vermaat JSP, Kalakonda N, Choquet S, Neste EVD, Hill B, Thieblemont C, Cavallo F, la Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi PF, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vassilakopoulos TP, Samal P, Ku M, Ma X, Chamoun K, Shah J, Canales M, Maerevoet M, Shacham S, Kauffman MG, Goy A
Jaar : 2022
Journal : Clin Lymphoma Myeloma Leuk
Volume : 22
Pagina's : 24-33

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.

Auteurs : Massaro F, Meuleman N, Bron D, Vercruyssen M, Maerevoet M
Jaar : 2022
Journal : Cancers (Basel)
Volume : 14

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.

Auteurs : Zijlstra JM, Follows G, Casasnovas RO, Vermaat JSP, Kalakonda N, Choquet S, Hill B, Thieblemont C, Cavallo F, Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vassilakopoulos TP, Samal P, Ku M, Xu J, Corona K, Chamoun K, Shah J, Canales M, Maerevoet M
Jaar : 2022
Journal : Cancers (Basel)
Volume : 14

Highlights In Lymphoma.

Auteurs : Maerevoet M
Jaar : 2021
Journal : Belgian J Hematology
Volume : 12(5)
Pagina's : 213-6

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.

Auteurs : Maerevoet M, Zijlstra JM, Follows G, Casasnovas RO, Vermaat JSP, Kalakonda N, Goy A, Choquet S, Van Den Neste E, Hill B, Thieblemont C, Cavallo F, De la Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vassilakopoulos TP, Samal P, Ku M, Ma X, Corona K, Chamoun K, Shah J, Shacham S, Kauffman MG, Canales M
Jaar : 2021
Journal : J Hematol Oncol
Volume : 14
Pagina's : 111

Intestinal presentation of non-Hodgkin lymphoma: Case report.

Auteurs : Kansoun A, Chamma L, Sadek M, Maerevoet M, Ghorra C, Abboud AA, Alam H
Jaar : 2021
Journal : Int J Surg Case Rep
Volume : 86
Pagina's : 106346

Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

Auteurs : Manson G, Brice P, Herbaux C, Silva MG, Bouabdallah K, Deau B, Bouteloup J, Schiano JM, Nicolas-Virelizier E, Maerevoet M, Ghesquieres H, Stamatoullas A, Antier C, Carlo-Stella C, de Charette M, Poizeau F, Dercle L, Houot R
Jaar : 2021
Journal : Eur J Nucl Med Mol Imaging
Volume : 48
Pagina's : 1144-1153

Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Auteurs : Shah J, Shacham S, Kauffman M, Daniele P, Tomaras D, Tremblay G, Casasnovas RO, Maerevoet M, Zijlstra J, Follows G, P Vermaat JS, Kalakonda N, Goy AH, Choquet S, Den Neste EV, Hill BT, Thieblemont C, Cavallo F, la Cruz F, Kuruvilla J, Hamad N, Bouabdallah R, Jäger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vasilakopoulos TP, Samal P, Nagy A, Ku M, Canales Albendea MÁ
Jaar : 2021
Journal : Future Oncol
Volume : 17
Pagina's : 1295-1310

Correction to: Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma.

Auteurs : Manson G, Brice P, Herbaux C, Silva MG, Bouabdallah K, Deau B, Bouteloup J, Schiano JM, Nicolas-Virelizier E, Maerevoet M, Ghesquieres H, Stamatoullas A, Antier C, Carlo-Stella C, de Charette M, Poizeau F, Dercle L, Houot R
Jaar : 2021
Journal : Eur J Nucl Med Mol Imaging
Volume : 48
Pagina's : 1699-1700

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.

Auteurs : Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA
Jaar : 2020
Journal : Lancet Haematol
Volume : 7
Pagina's : e511-e522

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

Auteurs : Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O
Jaar : 2019
Journal : Lancet Haematol
Volume : 6
Pagina's : e48-e57

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.

Auteurs : Houot R, Cartron G, Bijou F, de Guibert S, Salles GA, Fruchart C, Bouabdallah K, Maerevoet M, Feugier P, Le Gouill S, Tilly H, Casasnovas RO, Moluçon-Chabrot C, Van Den Neste E, Zachee P, Andre M, Bonnet C, Haioun C, van Hoof A, Van Eygen K, Molina L, Nicolas-Virelizier E, Ruminy P, Morschhauser F
Jaar : 2019
Journal : Leukemia
Volume : 33
Pagina's : 776-780

Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphoma.

Auteurs : Letourneau A, Maerevoet M, Milowich D, de Wind R, Bisig B, Missiaglia E, de Leval L
Jaar : 2018
Journal : Virchows Arch
Volume : 473
Pagina's : 505-511

The light chain IgLV3-21 defines a new poor prognostic subgroup in Chronic Lymphocytic Leukemia: results of a multicenter study.

Auteurs : Stamatopoulos B, Smith T, Crompot E, Pieters K, Clifford R, Mraz M, Robbe P, Burns A, Timbs A, Bruce DR, Hillmen P, Meuleman N, Mineur P, Firescu R, Maerevoet M, de Wilde V, Efira AA, Philippé J, Verhasselt B, Offner F, Sims D, Heger A, Dreau H, Schuh A
Jaar : 2018
Journal : Clin Cancer Res
Volume : 24(20)
Pagina's : 5048-5057

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.

Auteurs : Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H
Jaar : 2018
Journal : Am J Hematol

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Auteurs : Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C, + collaborators (among others :, Maerevoet M
Jaar : 2018
Journal : Cancer Med
Volume : 7
Pagina's : 539-548

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Auteurs : Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A
Jaar : 2017
Journal : Clin Cancer Res
Volume : 23(21)
Pagina's : 6411-6420